Director/PDMR Shareholding

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Director's Dealing

Oxford and Newcastle, UK, 12 May 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery and development company, announces that application has been made to AIM for the admission of 29,376 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares").

Professor Trevor Jones (Non-Executive Director) has subscribed for the New Ordinary Shares. The subscription monies paid for the New Ordinary Shares represent 50% of his fees net of tax paid during the period from 28 October 2015 to 30 April 2016. Professor Jones invested in the new ordinary shares on 11 May 2016 at an average price of 19.14 pence per share. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Admission of the 29,376 New Ordinary Shares to trading on AIM ("Admission") is expected to occur on 17 May 2016. Following Admission, Professor Jones will be interested in a total of 29,376 ordinary shares of 0.1p in the Company, representing approximately 0.01% of the Company's issued share capital.

Following Admission the total number of ordinary shares in the Company with voting rights in issue will be 264,484,927. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

-Ends-

Contacts:

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery. 

e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.